PL355292A1 - Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics - Google Patents

Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Info

Publication number
PL355292A1
PL355292A1 PL00355292A PL35529200A PL355292A1 PL 355292 A1 PL355292 A1 PL 355292A1 PL 00355292 A PL00355292 A PL 00355292A PL 35529200 A PL35529200 A PL 35529200A PL 355292 A1 PL355292 A1 PL 355292A1
Authority
PL
Poland
Prior art keywords
combinations
dioxino
neuroleptics
benzylamino
indol
Prior art date
Application number
PL00355292A
Other languages
English (en)
Polish (pl)
Inventor
Karen Lovell Marquis
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of PL355292A1 publication Critical patent/PL355292A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL00355292A 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics PL355292A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45860799A 1999-12-10 1999-12-10

Publications (1)

Publication Number Publication Date
PL355292A1 true PL355292A1 (en) 2004-04-05

Family

ID=23821437

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00355292A PL355292A1 (en) 1999-12-10 2000-12-07 Combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics

Country Status (20)

Country Link
EP (1) EP1235570A2 (xx)
JP (1) JP5557409B2 (xx)
KR (1) KR100772854B1 (xx)
CN (1) CN1230164C (xx)
AR (1) AR026756A1 (xx)
AU (1) AU784211B2 (xx)
BR (1) BR0016168A (xx)
CA (1) CA2396351C (xx)
CZ (1) CZ20021880A3 (xx)
EA (1) EA005002B1 (xx)
HK (1) HK1045942A1 (xx)
HU (1) HUP0203309A3 (xx)
IL (2) IL149669A0 (xx)
MX (1) MXPA02005649A (xx)
NO (1) NO20022739D0 (xx)
NZ (1) NZ519381A (xx)
PL (1) PL355292A1 (xx)
TW (1) TWI222864B (xx)
WO (1) WO2001041750A2 (xx)
ZA (1) ZA200205484B (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101409724B1 (ko) 2003-10-29 2014-06-19 와이어쓰 엘엘씨 아플린도어 및 이의 유도체를 포함하는 서방성 약제학적조성물
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
ES2430622T3 (es) * 2008-02-13 2013-11-21 Targacept, Inc. Combinación de agonistas nicotínicos alfa 7 y antipsicóticos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2987484B2 (ja) * 1995-03-16 1999-12-06 大塚製薬 株式会社 カルボスチリル誘導体の製造方法
US5756532A (en) * 1995-11-06 1998-05-26 American Home Products Corporation Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives
GB9627005D0 (en) * 1996-12-27 1997-02-12 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
AU1949001A (en) 2001-06-18
MXPA02005649A (es) 2004-09-10
WO2001041750A3 (en) 2002-02-14
KR100772854B1 (ko) 2007-11-02
IL149669A0 (en) 2002-11-10
IL149669A (en) 2006-06-11
ZA200205484B (en) 2003-12-31
CN1230164C (zh) 2005-12-07
JP5557409B2 (ja) 2014-07-23
HK1045942A1 (zh) 2002-12-20
EA200200656A1 (ru) 2002-12-26
CZ20021880A3 (cs) 2002-08-14
BR0016168A (pt) 2002-08-20
EP1235570A2 (en) 2002-09-04
WO2001041750A2 (en) 2001-06-14
AR026756A1 (es) 2003-02-26
KR20030016207A (ko) 2003-02-26
JP2003516350A (ja) 2003-05-13
NO20022739L (no) 2002-06-07
CA2396351A1 (en) 2001-06-14
HUP0203309A3 (en) 2004-12-28
NZ519381A (en) 2004-04-30
NO20022739D0 (no) 2002-06-07
CA2396351C (en) 2009-11-10
TWI222864B (en) 2004-11-01
HUP0203309A2 (hu) 2003-01-28
EA005002B1 (ru) 2004-10-28
AU784211B2 (en) 2006-02-23
CN1409633A (zh) 2003-04-09

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
TWI265808B (en) Valdecoxib compositions
EP1259240B8 (en) Agents, such as nicotinamide or cadpr for the treatment of skin disorders
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
HUP0104795A3 (en) Azabicycloalkanes as ccr5 modulators, pharmaceutical compositions comprising thereof and their use
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
IL140588A0 (en) Therapeutic composition based on flavonoids intended to be used in the treatment of tumours by cytotoxic agents
GR1003490B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας παροξετινης
SE0001916D0 (sv) Novel formulation
MXPA02005649A (es) Nuevas combinaciones terapeuticas de (s)-2 -(bencilamino -metil)-2, 3, 8, 9-tetrahidro-7h -1, 4-dioxino(2-3 -e]indol-8 -ona y agentes neurolepticos para el tratamiento o prevencion de trastornos psicoticos.
AP2000001946A0 (en) Form V1 5,6-Dichloro-2-(isopropylamino)-1-(B-L-Ribofuranosyl)-1H- benzimidazole.
BG104914A (en) Paroxetine maleate
JO2199B1 (en) Replaced pyrrols
WO2004006887A3 (en) Composition and methods for the treatment of skin disorders
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
AU3992897A (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psycho-intellectual disorders
AU2002357691A1 (en) Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
TNSN00242A1 (en) VALDECOXIB COMPOSITIONS

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)